Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH-1 phase 3 trial of efimosfermin alfa in biopsy-confirmed MASH with F2-F3 fibrosis
MOH_2026-05-06_015804Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by GSK. Primary endpoints: Fibrosis improvement without worsening steatohepatitis at week 52, Steatohepatitis resolution without worsening fibrosis at week 52 and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2026-05-06_015804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-06_015804.